Beyond Air Inc Dossier - Source-backed chat

Beyond Air Inc

XAIRNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.45

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.76Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.7M

Enterprise Value $7.8M

Shares Outstanding 984.4K diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) through its proprietary LungFit platform, which generates NO from ambient air. While the company has demonstrated strong top-line growth, with quarterly revenues exceeding $2.0 million (a 105% year-over-year increase), it continues to face significant financial and regulatory pressures. The transition to a new CEO, Robert Goodman, in March 2026 signals a strategic shift toward commercial execution. However, persistent net losses, high cash burn, and the immediate threat of Nasdaq delisting (requiring a reverse stock split to regain compliance by July 31, 2026) warrant a cautious 'Hold' recommendation until commercial scaling of the second-generation LungFit PH system is realized and the cash runway is stabilized.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$40.00

Mean target$160.00

High · most bullish analyst$280.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.3415%

The bear case materializes if the FDA delays clearance of the second-generation LungFit PH system beyond 2026, severely limiting commercial adoption. Furthermore, if the company fails to maintain its Nasdaq listing or experiences accelerated cash burn, it may face severe dilution under its equity line of credit or struggle to secure additional capital, leading to insolvency risks.

Base CaseCentral scenario

$0.6560%

The base case assumes steady but gradual commercial progress with the first-generation LungFit PH system in the U.S. and select international markets. Revenue for the fiscal year ending March 31, 2026, is expected to meet the guided range of $8.0 million to $10.0 million. The company successfully executes a reverse stock split to maintain its Nasdaq listing. Cash runway is extended into calendar 2027 through the Streeterville Capital promissory note and equity line of credit, but profitability remains several years away.

Bull CaseUpside scenario

$8.0025%

The bull case is driven by rapid market adoption of the second-generation LungFit PH system following anticipated FDA clearance in late 2026. This system's reduced weight, smaller footprint, and compatibility with air and ground transport address the primary objections of hospitals, allowing Beyond Air to aggressively capture market share from cylinder-based competitors like Mallinckrodt. International expansion across 40 countries and clinical progress in the Beyond Cancer (UNO program) and NeuroNOS (autism) pipelines could unlock substantial long-term value, driving the stock toward analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary tankless technology that generates nitric oxide from ambient air, eliminating the logistical and safety challenges of high-pressure cylinders.
Strong top-line momentum with over 100% year-over-year revenue growth in recent quarters.
Experienced commercial leadership under newly appointed CEO Robert Goodman to drive hospital adoption.
Broad pipeline potential with applications in solid tumors (Beyond Cancer) and neurological conditions (NeuroNOS).

Key Investment Risks

High cash burn rate relative to current cash reserves, requiring ongoing reliance on debt and equity financing.
Delisting risk from the Nasdaq Capital Market if the company fails to regain compliance with the $1.00 minimum bid price rule by July 31, 2026.
Intense competition from established, well-capitalized players like Mallinckrodt (INOmax) and Vero Biotech (Genosyl).
Regulatory risks associated with the pending FDA clearance of the second-generation LungFit PH system.

Thesis Invalidation Triggers

Failure to regain compliance with Nasdaq's minimum bid price rule by July 31, 2026, resulting in delisting.
FDA rejection or significant delay of the PMA supplement for the second-generation LungFit PH system.
Quarterly revenue growth stalling or declining sequentially, indicating a failure of the commercial strategy.
Inability to access the Streeterville Capital equity line of credit due to failure to meet customary conditions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.